• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利斯的明治疗帕金森病相关痴呆。

Rivastigmine for the treatment of dementia associated with Parkinson's disease.

机构信息

Movement Disorders Program, Department of Neurology, Medical College of Georgia, Augusta, GA, USA.

出版信息

Neuropsychiatr Dis Treat. 2007 Dec;3(6):775-83. doi: 10.2147/ndt.s1134.

DOI:10.2147/ndt.s1134
PMID:19300613
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2656320/
Abstract

Parkinson's disease (PD) afflicts millions of people worldwide and leads to cognitive impairment or dementia in the majority of patients over time. Parkinson's disease dementia (PDD) is characterized by deficits in attention, executive and visuospatial function, and memory. The clinical diagnostic criteria and neuropathology surrounding PDD remain controversial with evidence of overlap among PDD, dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Cortical cholinergic deficits are greater in PDD than in AD, and are well-correlated with the cognitive and neuropsychiatric dysfunction that occurs in PDD. Inhibition of acetylcholine metabolism is therefore a practical therapeutic strategy in PDD.This review examines current evidence for rivastigmine (a cholinesterase/butyrylcholinesterase inhibitor) treatment in PDD. In addition to its efficacy, we examine the safety profile, side effects, and cost effectiveness of rivastigmine in PDD. Rivastigmine provides modest benefit in PDD and further long-term studies are needed to determine the effectiveness and safety of rivastigmine over time. Tolerability is a problem for many PDD patients treated with rivastigmine. Future studies of rivastigmine in PDD should focus on pragmatic outcomes such as time to need for nursing home placement, pharmacoeconomic outcomes and simultaneous patient/caregiver quality of life assessments.

摘要

帕金森病(PD)影响着全球数以百万计的人,并导致大多数患者随着时间的推移认知能力下降或出现痴呆。帕金森病痴呆(PDD)的特点是注意力、执行和视空间功能以及记忆缺陷。PDD 的临床诊断标准和神经病理学仍然存在争议,其与路易体痴呆(DLB)和阿尔茨海默病(AD)之间存在重叠证据。与 AD 相比,PDD 中的皮质胆碱能缺陷更大,并且与 PDD 中发生的认知和神经精神功能障碍密切相关。因此,抑制乙酰胆碱代谢是 PDD 的一种实用治疗策略。

这篇综述检查了目前在 PDD 中使用rivastigmine(一种乙酰胆碱酯酶/丁酰胆碱酯酶抑制剂)治疗的证据。除了其疗效外,我们还检查了rivastigmine 在 PDD 中的安全性概况、副作用和成本效益。rivastigmine 在 PDD 中提供了适度的益处,需要进一步的长期研究来确定其在一段时间内的有效性和安全性。许多接受 rivastigmine 治疗的 PDD 患者耐受性差。未来关于 PDD 中 rivastigmine 的研究应侧重于实用结果,如需要入住养老院的时间、药物经济学结果以及同时对患者/护理人员的生活质量进行评估。

相似文献

1
Rivastigmine for the treatment of dementia associated with Parkinson's disease.利斯的明治疗帕金森病相关痴呆。
Neuropsychiatr Dis Treat. 2007 Dec;3(6):775-83. doi: 10.2147/ndt.s1134.
2
Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.路易体痴呆与帕金森病痴呆:当前的概念和争议。
J Neural Transm (Vienna). 2018 Apr;125(4):615-650. doi: 10.1007/s00702-017-1821-9. Epub 2017 Dec 8.
3
Cholinesterase inhibitors for Parkinson's disease dementia.用于帕金森病痴呆的胆碱酯酶抑制剂。
Cochrane Database Syst Rev. 2006 Jan 25(1):CD004747. doi: 10.1002/14651858.CD004747.pub2.
4
Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?路易体痴呆和帕金森病痴呆是同一种疾病吗?
BMC Med. 2018 Mar 6;16(1):34. doi: 10.1186/s12916-018-1016-8.
5
Rivastigmine and Parkinson dementia complex.卡巴拉汀与帕金森病痴呆综合征
Expert Opin Pharmacother. 2007 Apr;8(6):817-29. doi: 10.1517/14656566.8.6.817.
6
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.卡巴拉汀:乙酰胆碱酯酶和丁酰胆碱酯酶双重抑制的优势及其在皮质下血管性痴呆和帕金森病痴呆中的作用。
Clin Interv Aging. 2017 Apr 18;12:697-707. doi: 10.2147/CIA.S129145. eCollection 2017.
7
Dementia with Lewy Bodies versus Alzheimer's Disease and Parkinson's Disease Dementia: A Comparison of Cognitive Profiles.路易体痴呆与阿尔茨海默病和帕金森病痴呆的比较:认知特征分析。
J Clin Neurol. 2011 Mar;7(1):19-24. doi: 10.3988/jcn.2011.7.1.19. Epub 2011 Mar 31.
8
Diagnosis and management of Parkinson's disease dementia.帕金森病痴呆的诊断与管理
Int J Clin Pract. 2008 Oct;62(10):1581-7. doi: 10.1111/j.1742-1241.2008.01869.x.
9
Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis.用于帕金森病痴呆和路易体痴呆的胆碱酯酶抑制剂和美金刚:一项荟萃分析。
Exp Ther Med. 2019 Mar;17(3):1611-1624. doi: 10.3892/etm.2018.7129. Epub 2018 Dec 24.
10
Rivastigmine in Parkinson's disease dementia.卡巴拉汀治疗帕金森病痴呆
Expert Rev Neurother. 2008 Aug;8(8):1181-8. doi: 10.1586/14737175.8.8.1181.

引用本文的文献

1
Unveiling mysteries of aging: the potential of melatonin in preventing neurodegenerative diseases in older adults.揭开衰老之谜:褪黑素在预防老年人神经退行性疾病方面的潜力。
Biogerontology. 2025 Jun 24;26(4):125. doi: 10.1007/s10522-025-10254-7.
2
Effectiveness of a home-based computerized cognitive training in Parkinson's disease: a pilot randomized cross-over study.帕金森病家庭式计算机认知训练的有效性:一项试点随机交叉研究。
Front Psychol. 2025 Jan 9;15:1531688. doi: 10.3389/fpsyg.2024.1531688. eCollection 2024.
3
Transient receptor potential V1 modulates neuroinflammation in Parkinson's disease dementia: Molecular implications for electroacupuncture and rivastigmine.瞬时受体电位香草酸亚型1调节帕金森病痴呆中的神经炎症:对电针和卡巴拉汀的分子学启示
Iran J Basic Med Sci. 2021 Oct;24(10):1336-1345. doi: 10.22038/IJBMS.2021.56156.12531.
4
Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias.在非阿尔茨海默病痴呆中使用胆碱酯酶抑制剂。
Drugs Aging. 2019 Aug;36(8):719-731. doi: 10.1007/s40266-019-00685-6.
5
Therapeutic approaches in Parkinson's disease and related disorders.帕金森病及相关疾病的治疗方法。
J Neurochem. 2016 Oct;139 Suppl 1(Suppl 1):346-352. doi: 10.1111/jnc.13529. Epub 2016 Feb 10.
6
Combination therapies: The next logical Step for the treatment of synucleinopathies?联合疗法:治疗突触核蛋白病的下一个合理步骤?
Mov Disord. 2016 Feb;31(2):225-34. doi: 10.1002/mds.26428. Epub 2015 Sep 21.

本文引用的文献

1
Mild cognitive impairment in Parkinson's disease: the challenge and the promise.帕金森病患者的轻度认知障碍:挑战与希望。
Neuropsychiatr Dis Treat. 2005 Mar;1(1):37-50. doi: 10.2147/nedt.1.1.37.52295.
2
Clinical phenotype of Parkinson disease dementia.帕金森病痴呆的临床表型
Neurology. 2006 Nov 14;67(9):1605-11. doi: 10.1212/01.wnl.0000242630.52203.8f.
3
Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.卡巴拉汀对帕金森病合并痴呆患者震颤的影响。
Mov Disord. 2006 Oct;21(10):1663-6. doi: 10.1002/mds.20971.
4
Deep brain stimulation: neuropsychological and neuropsychiatric issues.深部脑刺激:神经心理学和神经精神学问题。
Mov Disord. 2006 Jun;21 Suppl 14:S305-27. doi: 10.1002/mds.20963.
5
Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.卡巴拉汀在路易体痴呆和帕金森病痴呆中的心脏安全性。
Int J Clin Pract. 2006 Jun;60(6):639-45. doi: 10.1111/j.1368-5031.2006.00967.x.
6
Parkinson's disease and dementia.帕金森病与痴呆症。
Neurol Sci. 2006 Mar;27 Suppl 1:S40-3. doi: 10.1007/s10072-006-0546-6.
7
Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies.帕金森病、帕金森病痴呆和路易体痴呆中的运动亚型与认知衰退
J Neurol Neurosurg Psychiatry. 2006 May;77(5):585-9. doi: 10.1136/jnnp.2005.081711.
8
Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:帕金森病抑郁、精神病和痴呆的评估与治疗(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2006 Apr 11;66(7):996-1002. doi: 10.1212/01.wnl.0000215428.46057.3d.
9
International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study.帕金森病首个综合性自我完成非运动症状问卷的国际多中心试点研究:NMSQuest研究。
Mov Disord. 2006 Jul;21(7):916-23. doi: 10.1002/mds.20844.
10
Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.卡巴拉汀用于帕金森病痴呆患者的经济学评估。
Pharmacoeconomics. 2006;24(1):93-106. doi: 10.2165/00019053-200624010-00008.